Fractyl Health, Inc. (GUTS)
| Market Cap | 71.98M |
| Revenue (ttm) | 3,000 |
| Net Income (ttm) | -122.20M |
| Shares Out | 153.37M |
| EPS (ttm) | -2.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,839,611 |
| Open | 0.473 |
| Previous Close | 0.475 |
| Day's Range | 0.455 - 0.473 |
| 52-Week Range | 0.377 - 3.030 |
| Beta | 1.63 |
| Analysts | Strong Buy |
| Price Target | 5.40 (+1,050.65%) |
| Earnings Date | Mar 3, 2026 |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering me... [Read more]
Financial Performance
In 2024, Fractyl Health's revenue was $93,000, a decrease of -22.50% compared to the previous year's $120,000. Losses were -$70.43 million, -25.29% less than in 2023.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for GUTS stock is "Strong Buy." The 12-month stock price target is $5.4, which is an increase of 1,050.65% from the latest price.
News
Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026 Company reiterates cash runway guidance into early 2027, beyond anti...
Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts
Fractyl Health offers a buy-the-dip opportunity after an overreaction to underwhelming 6-month pilot data for its Revita device. Revita's pivotal Phase 3 obesity trial is well-funded, with topline res...
Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS
LOS ANGELES--(BUSINESS WIRE)--Fractyl Health, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – GUTS.
Fractyl Health Shares Drop, Eyes New FDA Route For Its Lead Product
Fractyl Health Inc. (NASDAQ: GUTS) stock plunged on Thursday after the company hinted at a change in its U.S. regulatory strategy for Revita.
Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health, Inc. (GUTS) Discusses REMAIN-1 Midpoint Cohort Results on Revita for Weight Maintenance After GLP-1 Discontinuation Transcript
Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolera...
Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that trea...
Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approxima...
Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
BURLINGTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pioneering pattern-breaking approache...
Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Participants who lost 24% total body weight (>50 lbs.) on GLP-1 drugs maintained stable weight 6 months after GLP-1 discontinuation and single Revita treatment
Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat ro...
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Fractyl Health, Inc. ( GUTS) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Brian Luque - Head of Investor Relations & Corporate Development Harith Rajagopalan - Co-Founder,...
Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
Positive randomized 3-month REMAIN-1 Midpoint Cohort data showed single Revita procedure maintained weight loss after GLP-1 discontinuation; 6-month data expected in Q1 2026 6-month data from open-lab...
Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes...
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
RJVA-002 achieved ~30% weight loss at five weeks in a translational obesity model; weight loss not yet plateaued Preclinical results show that a single point-in-time treatment with RJVA-002 has the po...
Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang
Fractyl Health delivered best-case results from its REMAIN-1 trial, with Revita patients continuing weight loss after GLP-1 discontinuation while placebo significantly rebounded. GUTS is still ~$230 m...
Fractyl Health, Inc. - Special Call
Fractyl Health, Inc. - Special Call Company Participants Brian Luque Harith Rajagopalan - Co-Founder, CEO & Director Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Res...
Fractyl Health says experimental procedure helps maintain weight-loss in study
Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday.
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “F...
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
Pilot study met key 3-month efficacy endpoint with strong statistical significance (p=0.014); Revita-treated patients lost an additional 2.5% total body weight after stopping GLP-1 drugs vs. 10% regai...
Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward
Fractyl Health's Revita offers a one-time procedure to maintain GLP-1 weight loss, with pivotal 45-patient trial data expected imminently. Early open-label results show Revita may significantly reduce...
Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth
Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors Appointments include Christopher Thompson, M.D. and Ian Sheffield as Independent Directors
Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian Luque - Corporate Participant Harith Rajagopalan - Co-Founder, CEO & Director...
Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates
Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025 Positive 3-month REVEAL-1 Cohort data showed single Revita ® procedure sustained weight loss after GLP-1 discontinuation; in...
Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares
Offering included participation from leading institutional investors, including Nantahala Capital, ADAR1 Capital Management, Second Line Capital, 683 Capital, and SilverArc Capital Proceeds expected t...